/
Oncology
Papilloma
23
Pipeline Programs↗
29
Active Trials↗
17
Companies Involved↗
Papilloma is an emerging landscape with 23 programs across 17 companies. The most active players are SymBio Pharmaceuticals. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 12
Phase 27
Phase 36
Approved
No programs
Analysis
Modality Breakdown
19programs
Small molecule842%
Vaccine632%
Monoclonal antibody211%
Cell therapy211%
Protein / enzyme15%
Modality classified for 100% of 23 pipeline programs.
Analysis
Trial Status
170
clinical trials
Completed104 · 61%
Unknown status20 · 12%
Active, not recruiting16 · 9%
Terminated11 · 6%
Recruiting10 · 6%
Withdrawn6 · 4%
Other3 · 2%
Clinical Trials
Trial Activity
170 trials
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Recruiting·—·Phase 2·NCT06793410·100 enrolled
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Recruiting·—·Phase 2·NCT05686226·20 enrolled
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
Active, not recruiting·NNational Vaccine and Serum Institute, China·Phase 3·NCT06632912·1,800 enrolled
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
Active, not recruiting·—·Phase 4·NCT03391921·170 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)